PPRC1 and cancer: PSMA, as well as other targeting ligand candidates (reviewed in Hu et al., 2024) [12], were selected because of their overabundance of PrC cells rather than for their ability to initiate effective carrier-drug uptake and intracellular drug delivery, factors that ultimately limit the efficacy of targeted drug therapy for cancer.